Compass Therapeutics upgraded by Leerink Partners with a new price target

4/2/25 8:43:28 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Leerink Partners upgraded Compass Therapeutics from Market Perform to Outperform and set a new price target of $6.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CMPX

Date	Price Target	Rating	Analyst
4/2/2025	$6.00	Market Perform → Outperform	Leerink Partners
2/24/2025	$12.00	Buy	Guggenheim
2/19/2025	$12.00	Overweight	Piper Sandler
12/23/2024	$32.00	Buy	D. Boral Capital
11/15/2024	$5.00 → $4.00	Outperform → Market Perform	Leerink Partners
9/16/2024	$5.00	Neutral → Buy	Ladenburg Thalmann
1/31/2023	$8.00	Buy	Jefferies
1/27/2023	$9.00	Buy	Stifel